Cannabis Product Variety Set to Expand

As Canada’s implementation of recreational cannabis laws inches closer, companies are moving swiftly to lock in licensing and regulatory agreements. Implementation in Canada is set for October 17th, which will be a huge milestone for the industry globally. Canada will become only the second country to legalize cannabis nationwide, alongside Uruguay. Despite the two countries legalizing cannabis, the United States still dominates the market, contributing over 90% of the revenue last year. According to Arcview Market Research in partnership with BDS Analytics, the market is projected to continue growing, as it already increased by 31% in 2017. Consumer spending is projected to increase at a CAGR of 22% by 2023. Although, medical cannabis sales still control the market, in U.S. states where it legalized entirely, recreational sales are beginning to overshadow medical sales.

As many countries and states within the U.S. turn to voting for legalization whether for medical or recreational purposes, it signifies a new market emerging. The market is already highly competitive, which has led companies to look into new sub-segments, leading companies to expand while also introducing new players. Global expansion and diversity of company portfolio’s have interested the investing community, showing how quickly the market is growing despite prohibitions. Tilray Inc. (NASDAQ: TLRY) is among one of the top cannabis companies expanding rapidly in both market segments. Recently, Tilray acquired Alef Biotechnology, which establishes its presence in Latin America. Last month, Tilray complete shipments of cannabis, both medical and recreational, to Germany and the United Kingdom.

Global expansion is still predominantly led by medical cannabis growth due to regulatory laws. Recreational-based companies are looking to enter mainly into the U.S. and Canada, while providing supply overseas. For the U.S., companies are beginning to target states that are in the process of voting. Specifically, states such as Michigan, Utah, New Jersey and Massachusetts are set to vote in the upcoming elections. According to Grand View Research, the U.S. legal cannabis market was worth approximately USD 7.06 Billion in 2016 and its projected to grow at a CAGR of 24.9% from 2017 to 2025.

Obtaining licensing permits to run dispensaries and cultivation sites is competitive. In Massachusetts, as of late September, there were 15 businesses with provisional retail licenses, according to the Cannabis Control Commission, increasing the total to 38. Most of the businesses revolve around retail, cultivation and product manufacturing. Meanwhile, Colorado, which was the first state to legalize cannabis, had a total of 364 dispensaries alone operating earlier this year.

The statistics compared to Massachusetts and Colorado show that Massachusetts is still at its infancy stage and that there’s much more room for the state to grow, especially Suffolk County, home to Boston, which has not yet issued a license to any recreational cannabis operators. There are already established businesses in Massachusetts who have received licensing early on such as AmeriCann, Inc. (OTCQB: ACAN), which has secured the purchase of property in Southeastern Massachusetts. The property, which will be known as the Massachusetts Medical Cannabis Center or “MMCC”, will include greenhouse cultivation, processing and infused product facilities. To expand the facility, AmeriCann plans operate a second building to produce branded cannabis beverages, vaporizer products, edible and non-edible products and concentrates. The facility is set to open in early Spring 2019.

States like Massachusetts that are beginning to legalize cannabis highlight the widespread effect cannabis is having. As states and even nations beginning to reduce regulations, new companies still have plenty of opportunities to enter into the industry.

Sponsored Content Release. Click for Full Disclosure

  1. Majorie Hopkins 6 months ago

    After suffering for years with chronic nausea as a result from damage from Severe food poisoning and misdiagnoses leading to even more Severe complications, smoking medical cannabis finally gives me relief from the constant urge to vomit, as well as my overwhelming fibro.

  2. Rab Docherty 6 months ago

    “Medical cannabis,” (CBD) is effectively an excellent pain reliever. CBD + THC Cannabis Oil is the CURE and is illegal. Cannabis extracts engage our body’s endocannabinoid system

    • Tracey Ann 6 months ago

      all the meds I have been on for epilepsy for the past 20 years do nothing but cost NHS money ..cannabis works so much better than any “cost a fortune” pill

Leave a Comment

  • Sponsored Content Release, a leading financial news informational web portal designed to provide the latest trends in Market News, Investing News, Personal Finance, Politics, Entertainment, in-depth broadcasts on Stock News, Market Analysis and Company Interviews. A pioneer in the financially driven digital space, video production and integration of social media, creates 100% unique original content. also provides financial news PR dissemination, branding, marketing and advertising for third parties for corporate news and original content through our unique media platform that includes Newswire Delivery, Digital Advertising, Social Media Relations, Video Production, Broadcasting, and Financial Publications.

    Please Note: is not a financial advisory or advisor, investment advisor or broker-dealer and do not undertake any activities that would require such registration. The information provided on (the ‘Site’) is either original financial news or paid advertisements provided [exclusively] by our affiliates (sponsored content),, a financial news media and marketing firm enters into media buys or service agreements with the companies which are the subject to the articles posted on the Site or other editorials for advertising such companies. We are not an independent news media provider and therefore do not represent or warrant that the information posted on the Site is accurate, unbiased or complete. receives fees for producing and presenting high quality and sophisticated content on along with other financial news PR media services. does not offer any personal opinions, recommendations or bias commentary as we purely incorporate public market information along with financial and corporate news. only aggregates or regurgitates financial or corporate news through our unique financial newswire and media platform. For Americann Inc. financial and corporate news dissemination, has been compensated five thousand dollars by axiom group. Our fees may be either a flat cash sum or negotiated number of securities of the companies featured on this editorial or site, or a combination thereof. The securities are commonly paid in segments, of which a portion is received upon engagement and the balance is paid on or near the conclusion of the engagement. will always disclose any compensation in securities or cash payments for financial news PR advertising. does not undertake to update any of the information on the editorial or Site or continue to post information about any companies the information contained herein is not intended to be used as the basis for investment decisions and should not be considered as investment advice or a recommendation. The information contained herein is not an offer or solicitation to buy, hold or sell any security., members and affiliates are not responsible for any gains or losses that result from the opinions expressed on this editorial or Site, company profiles, quotations or in other materials or presentations that it publishes electronically or in print. Investors accept full responsibility for any and all of their investment decisions based on their own independent research and evaluation of their own investment goals, risk tolerance, and financial condition. By accessing this editorial and website and any pages thereof, you agree to be bound by the Terms of Use and Privacy Policy, as may be amended from time to time. None of the content issued by constitutes a recommendation for any investor to purchase, hold or sell any particular security, pursue a particular investment strategy or that any security is suitable for any investor. This publication is provided by Each investor is solely responsible for determining whether a particular security or investment strategy is suitable based on their objectives, other securities holdings, financial situation needs, and tax status. You agree to consult with your investment advisor, tax and legal consultant before making any investment decisions. We make no representations as to the completeness, accuracy or timeless of the material provided. All materials are subject to change without notice. Information is obtained from sources believed to be reliable, but its accuracy and completeness are not guaranteed. For our full disclaimer, disclosure and Terms of Use, please visit: .